BCL2 and neuroblastoma: Furthermore, miR-15a directly targets Cripto, Bmi-1, CCNE1, RECK, VEGF, CCND1, and BCL-2 to suppress the malignant phenotypes in various tumors including NSCLC, pancreatic ductal adenocarcinoma, breast cancer, neuroblastoma, multiple myeloma, and osteosarcoma [20–22, 25–32].